This bill tightens rules on any exchange involving human fetal tissue. It broadens what counts as “something of value” to include almost any kind of payment or benefit—like cash, gifts, waived fees, forgiven debts, free or discounted services, and even payments tied to transporting, processing, preserving, quality control, storing, or implanting fetal tissue. By counting these as “valuable consideration,” the bill aims to block sales or related transactions involving fetal tissue altogether.

Key points

• Who is affected: Health care providers, clinics, researchers, tissue banks, and anyone who handles fetal tissue.
• What changes: Payments and benefits that used to look like reimbursements (for transport, processing, storage, etc.) would now count as “valuable consideration,” making exchanges involving fetal tissue broadly prohibited.
• Practical effect: Fewer or no financial exchanges of any kind would be allowed for fetal tissue, which could limit how it is moved, handled, or used in research or medical settings.